FG-3019 (pamrevlumab) is a human antibody specific for CTGF, and is currently under clinical trials for the treatment of IPF [27] and PDAC [28], which revealed improved pulmonary fibrosis in IPF and prolonged survival in PDAC. This evidence concerns the gene CCN2 and pulmonary fibrosis.